Journey Medical Corporation Reveals Promising Comparative Pharmacokinetic (PK) Data for DFD-29: A Step Towards Improved Medical Treatment
Journey Medical Corporation Announces Positive Comparative Phar… Phase 3 Registrational Studies Progressing Smoothly SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced positive PK comparability data. Exciting news…